Abstract | OBJECTIVE: METHODS: The engraftment, graft versus host disease (GVHD), infection, relapse, and survival of 13 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed. RESULTS: Thirteen (10 males and 3 females) CMML patients with a median age of 38 years old received allo-HSCT including 4 from HLA-matched unrelated donors, 6 from HLA-matched sibling donors and 3 from haploidentical related donors. All 13 patients achieved engraftment, and the median time of neutrophil engraftment and platelet engraftment were 12 (11-18) days and 15 (10-55) days respectively, acute GVHD occurred in 8 patients. After the median follow-up of 13 (6-29) months, the overall survival, disease free survival and relapse were 53.8%, 53.8%, 7.7%, respectively. CONCLUSION: Allo-HSCT can improve the survival of patients with CMML, and is a effective method for treatment of CMML.
|
Authors | Tong Wang, Wei-Yang Li, Xiao-Fei Qi, Ri Zhang, Zhen-Ming Jing, Hui-Ying Qiu, Yue Han, Xiao Ma, Cheng-Cheng Fu, Xiao-Wen Tang, Su-Ning Chen, Ai-Ning Sun, De-Pei Wu |
Journal | Zhongguo shi yan xue ye xue za zhi
(Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Vol. 23
Issue 6
Pg. 1667-72
(Dec 2015)
ISSN: 1009-2137 [Print] China |
PMID | 26708891
(Publication Type: Journal Article)
|
Topics |
- Adult
- Disease-Free Survival
- Female
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myelomonocytic, Chronic
- Male
- Retrospective Studies
- Siblings
- Tissue Donors
- Transplantation, Homologous
|